<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559347</url>
  </required_header>
  <id_info>
    <org_study_id>2007-48</org_study_id>
    <nct_id>NCT04559347</nct_id>
  </id_info>
  <brief_title>Local Anesthetic as Single Shot Versus Catheter in Patients Undergoing Video Assisted Thoracoscopic Surgery</brief_title>
  <official_title>Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivicaine) Versus Continuous Erector Spinae Plane Block Catheter in Patients Undergoing Video Assisted Thoracoscopic (VAT) Surgery; Single Center, Non Inferiority, Open Label, Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Guthrie Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Guthrie Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to compare a single shot long acting local anesthetic to&#xD;
      catheter infusion of local anesthetic in patients undergoing video assisted thoracoscopic&#xD;
      (VAT) surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research is to compare Single Shot Liposomal Bupivacaine&#xD;
      (EXPAREL®)/Bupivacaine (a long acting local anesthetic) to Ropivacaine (0.5% bolus followed&#xD;
      by 0.2% infusion of local anesthetic using a catheter) in patients undergoing video assisted&#xD;
      thoracoscopic (VAT) surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Compare Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine (a long acting local anesthetic) to Ropivacaine (0.5% followed by 0.2% infusion using a catheter) in patients undergoing video assisted thoracoscopic (VAT) surgery.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rated Pain Scale (NRP)</measure>
    <time_frame>3 days post-operative</time_frame>
    <description>Patient reported pain scale (0-10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative opioid consumption</measure>
    <time_frame>3 days post-operative</time_frame>
    <description>Post-operative opioid consumption in morphine equivalents to determine total morphine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Intraoperative narcotic</measure>
    <time_frame>At end of surgery</time_frame>
    <description>Total opioids administered in the operating room surgery in morphine equivalents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total adjunct pain medication consumption</measure>
    <time_frame>3 days post-operative</time_frame>
    <description>Non-narcotic pain medications such as acetaminophen, gabapentin, ketorolac, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incentive spirometry changes from preoperative baseline to 3 days post-operative</measure>
    <time_frame>3 days post-operative</time_frame>
    <description>Incentive spirometry change from preoperative baseline to 3 days post-operative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>From date of admission until date of discharge, an average of 3 days</time_frame>
    <description>Number of days from admission to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Quality of Recovery score (QOR-15)</measure>
    <time_frame>3 days post-operative</time_frame>
    <description>A survey on patient reported outcomes which consists of 15 questions related to five domains of patient reported health status (pain, physical comfort, physical independence, psychological support and emotional state). The score is reported on a scale from 0 to 150 with higher scores meaning a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events frequency</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Frequency and type of adverse events associated with Single Shot Liposomal Bupivacaine (Exparel)/Bupivacaine (SS) and Ropivacaine 0.5% BOLUS followed by Ropivacaine 0.2% continuous infusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Thoracic Surgery</condition>
  <arm_group>
    <arm_group_label>Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine for erector spinae block as local anesthetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous catheter infusion ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ropivacaine (0.5% bolus followed by 0.2% infusion) using a continuous catheter for erector spinae plane block as local anesthetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine (EXPAREL®)/Bupivacaine</intervention_name>
    <description>Single shot for erector spinae block</description>
    <arm_group_label>Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine</arm_group_label>
    <other_name>EXPAREL®/Bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine (0.5% bolus followed by 0.2% infusion)</intervention_name>
    <description>Continuous catheter infusion for erector spinae plane block</description>
    <arm_group_label>Continuous catheter infusion ropivacaine</arm_group_label>
    <other_name>Ropivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who are age &gt; 18, undergoing video thoracoscopic surgery and following&#xD;
             Guthrie Robert Packer Hospital's Enhanced Recovery After Surgery (ERAS) protocol for&#xD;
             Thoracic Surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  weight &lt; 50 kg, pregnant subjects,&#xD;
&#xD;
          -  left ventricular ejection fraction &lt; 30%,&#xD;
&#xD;
          -  history of drug or narcotic abuse,&#xD;
&#xD;
          -  history of allergic to amide local anesthetic,&#xD;
&#xD;
          -  presence of contraindication for erector spinae plane block (local skin infection,&#xD;
             sepsis, severe coagulopathy)&#xD;
&#xD;
          -  unable to provide consent,&#xD;
&#xD;
          -  unable to use pain rating scales as demonstrated by verbal feedback&#xD;
&#xD;
          -  preoperative chronic pain on narcotics,&#xD;
&#xD;
          -  history of renal insufficiency ( Creatinine &gt; 1.5 mg/dl),&#xD;
&#xD;
          -  preoperative mild liver impairment ( i.e. AST/ALT above 1.5 times the upper normal&#xD;
             limit)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poovendran Saththasivam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Guthrie Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Poovendran Saththasivam, MD</last_name>
    <phone>570-887-4676</phone>
    <email>Poovendran.Saththasivam@guthrie.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathaniel McElhaney, MD</last_name>
    <phone>570-887-2300</phone>
    <email>Nathaniel.McElhaney@guthrie.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Robert Packer Hospital</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Poovendran Saththasivam, MD</last_name>
      <phone>570-887-4676</phone>
      <email>Poovendran.Saththasivam@guthrie.org</email>
    </contact>
    <contact_backup>
      <last_name>Nathaniel McElhaney, MD</last_name>
      <phone>570-887-2300</phone>
      <email>Nathaniel.McElhaney@guthrie.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thoracic surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

